allinurl:tirzepatide FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders Tirzepatide / Niacinamide Injection |
Description
Participants switching from DPP-4 inhibitors may have required higher doses due to inadequate glycemic control with prior therapy
USA 107 , 93179322 (2010)
This might cause approval to be stalled for two years
To put this in context: tirzepatide (Mounjaro and Zepbound) and high-dose semaglutide (Wegovy) show the strongest signals, because they produce the greatest weight loss (tirzepatide around 21%, Wegovy around 15%)
Insurance verification occurs simultaneously
